×

Scientific References

NOW AVAILABLE: A More Objective and Comprehensive Diagnostic Testing Solution
for Difficult-to-Diagnose Melanocytic Lesions. LEARN MORE

myPath Melanoma Clinical Evidence

 

Clarke L, Mabey B, Flake D, et al. Clinical validity of a gene expression signature in diagnostically uncertain neoplasms. Per Med 2020;17:361-71.

 

Ko J, Clarke L, Minca E, et al. Correlation of melanoma gene expression score with clinical outcomes on a series of melanocytic lesions. Hum Pathol 2019;86:213-21.

 

Clarke L, Pimental J, Zalaznick H, et al. Gene expression signature as an ancillary method in the diagnosis of desmoplastic melanoma. Hum Pathol 2017;70:113-20.

 

Ko J, Matharoo-Ball B, Billings S, et al. Diagnostic distinction of malignant melanoma and benign nevi by a gene expression signature and correlation to clinical outcomes. Cancer Epidemiol Biomarkers Prev 2017;26:1107-13.

 

Clarke L, Flake D, Busam K, et al. An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi. Cancer 2016;123:617-28.

 

Warf MB, Flake D, Adams D, et al. Analytical validation of a melanoma diagnostic gene signature using formalin-fixed paraffin embedded melanocytic lesions. Biomark Med 2015;9:407-16.

 

Clarke L, Warf M, Flake D, et al. Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma. J Cutan Pathol 2015;42:244-52.

 

myPath Melanoma Clinical Impact Studies and Surveys 

 

Cockerell C, Tschen J, Billings S, et al. The influence of a gene-expression signature on the treatment of diagnostically challenging melanocytic lesions. Per Med 2017;14:123-30.

 

Cockerell C, Tschen J, Evans B, et al. The influence of a gene expression signature on the diagnosis and recommended treatment of melanocytic tumors by dermatopathologists. Medicine 2016;40:e4487.

 

Tschen J, Davies P, Meek S, et al. Clinical use of a diagnostic gene expression signature for melanocytic neoplasms.  

 

Guidelines, Criteria, and Staging Systems 

 

Cancer Stat Facts: Melanoma of the Skin  https://seer.cancer.gov/statfacts/html/melan.html Posted April 2020.

 

Piepkorn MW, Longton GM, Reisch, LM, et al.  Assessment of second-opinion strategies for diagnoses of cutaneous melanocytic lesions. JAMA Netw Open 2019;2:e1912597.

 

Elmore JG, Barnhill RL, Elder DE, et al. Pathologists’ diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study. BMJ 2017;357:j2813. 

 

Meyer A, Payne V, Meeks D, et al. Physicians’ diagnostic accuracy, confidence, and resource requests: a vignette study. JAMA Int Med 2013;173:1952-8.

 

Guy GP, Ekwueme DU, Tanga FK, et al. Melanoma treatment costs: a systematic review of the literature, 1990-2011. Am J Prev Med 2012;43:537-45.

 

Haws B, St Romain P, Mammen J et al.  Secondary review of external histopathology on cutaneous oncology patients referred for sentinel lymph node biopsy: how often does it happen and is it worth it? J Cutan Pathol 2012;39:844-9.

 

Gerami P, Barnhill RL, Beilfuss BA, et al. Superficial melanocytic neoplasms with pagetoid melanocytosis: a study of interobserver concordance and correlation with FISH. Am J Surg Pathol 2010;34:816-21.

 

Lodha S, Saggar S, Celebi JT, et al. Discordance in the histopathologic diagnosis of difficult melanocytic neoplasms in the clinical setting. J Cutan Pathol 2008;35:349-52.

 

Brochez L, Verhaeghe E, Grosshans E, et al.  Inter-observer variation in the histopathological diagnosis of clinically suspicious pigmented skin lesions.  J Pathol 2002;196:459-66.

 

Veenhuizen KC, De Wit PE, Mooi WJ, et al. Quality assessment by expert opinion in melanoma pathology: experience of the pathology panel of the Dutch Melanoma Working Party. J Pathol 1997;182:266-72.

DiffDx-Melanoma Clinical Evidence

 

Estrada SI, Shackelton JB, Cleaver NJ, et al. Development and validation of a diagnostic 35-gene expression profile test for ambiguous or difficult-to-diagnose suspicious pigmented skin lesions. SKIN: J Cutan Med 2020;4:506-22.

 

DiffDx-Melanoma Clinical Impact Studies and Surveys

 

Farberg AS, Ahmed KL, Bailey CN, et al. A 35-gene expression profile test for use in suspicious pigmented lesions impacts clinical management decisions of dermatopathologists and dermatologists. SKIN: J Cutan Med 2020;4:523-33.

 

DiffDx-Melanoma Clinical Posters and Presentations

 

Estrada SI, Shackelton JB, Martin HL, et al. Performance of a diagnostic 35-gene expression profile test (GEP) on difficult-to-diagnose melanocytic lesions. Poster at 10th World Congress of Melanoma/17th European Association of Dermato-Oncology (EADO) Congress; Apr 15-17, 2021; virtual. 

 

Estrada SI, Goldberg MS, Farberg AS, et al. Development, validation, and clinical utility of the 35-gene expression profile test for use as an adjunctive melanoma diagnostic tool. Poster at 10th World Congress of Melanoma/17th European Association of Dermato-Oncology (EADO) Congress; Apr 15-17, 2021; virtual.

 

Cockerell C, Goldberg MS, Estrada SI, et al. Performance of a 35-gene expression profile test in suspicious pigmented lesions of the head and neck.  Poster at 2021 Winter Clinical Dermatology Conference: January 15-24, 2021; Virtual. Poster #007.

 

Estrada, SI, Shackelton, JB, Cleaver, NJ, et al. Development and validation of a diagnostic gene expression profile test for ambiguous or difficult-to-diagnose pigmented skin lesions. ASDP20 Poster #296.

melhcp-riskidentified.svg

Order MyPath® Melanoma or DiffDx®-Melanoma

For Information

Call: 866-788-9007

Video Webinar

An introduction to our Comprehensive Diagnostic Offering by Castle Biosciences Medical Director Matthew Goldberg, MD.

Expert Opinions in Melanoma

When Is the myPath Melanoma Test Most Helpful

On-Demand
Educational Programs

What's Next?

Using DecisionDx®-Melanoma to Better Identify the Risk of Recurrence and Metastasis

How Do You Order a
myPath Melanoma and
DiffDx-Melanoma Test?

Scroll to Top